share_log

Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

新開源醫療控股有限公司(SZSE:300109)的股票走勢上升:強勁財務狀況引領市場?
Simply Wall St ·  10/03 20:08

Boai NKY Medical Holdings' (SZSE:300109) stock is up by a considerable 26% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Boai NKY Medical Holdings' ROE.

新開源醫療控股(SZSE:300109)的股票在過去一個月內大幅上漲了26%。鑑於該公司出色的表現,我們決定更加密切地研究其財務指標,因爲公司的財務狀況通常決定了市場的長期業績。在本文中,我們決定重點關注新開源醫療控股的roe。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

淨資產收益率(ROE)是衡量公司增值和管理投資者資金有效性的測試。換句話說,它是一種盈利能力比率,用於衡量公司股東提供的資金回報率。

How To Calculate Return On Equity?

如何計算股東權益報酬率?

ROE can be calculated by using the formula:

淨資產收益率可以使用以下公式進行計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益

So, based on the above formula, the ROE for Boai NKY Medical Holdings is:

因此,根據上述公式,新開源醫療控股的roe爲:

13% = CN¥440m ÷ CN¥3.4b (Based on the trailing twelve months to June 2024).

13% = 4.4億人民幣 ÷ 340億人民幣(截至2024年6月的過去十二個月)。

The 'return' is the yearly profit. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.13 in profit.

「回報率」是每年利潤。這意味着公司爲每個CN¥1的股東權益產生了CN¥0.13的利潤。

What Has ROE Got To Do With Earnings Growth?

roe與盈利增長有何關係?

So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前爲止,我們已經了解到roe是衡量公司盈利能力的指標。我們現在需要評估公司重新投資或「保留」的利潤量,從而給我們提供有關公司增長潛力的想法。其他條件相同的情況下,roe和利潤保留率均較高的公司通常是增長率比沒有這些特徵的公司高的公司。

Boai NKY Medical Holdings' Earnings Growth And 13% ROE

新開源醫療控股的盈利增長和13% roe

To start with, Boai NKY Medical Holdings' ROE looks acceptable. Further, the company's ROE compares quite favorably to the industry average of 6.4%. This probably laid the ground for Boai NKY Medical Holdings' significant 39% net income growth seen over the past five years. We believe that there might also be other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.

首先,新開源醫療控股的roe看起來是可以接受的。此外,公司的roe與行業平均水平6.4%相比相當可觀。這可能爲新開源醫療控股過去五年中顯著增長39%的淨利潤奠定了基礎。我們相信,可能還有其他一些積極影響公司盈利增長的方面。例如,公司的管理層可能已經做出了一些良好的戰略決策,或者公司的派息率較低。

Next, on comparing with the industry net income growth, we found that Boai NKY Medical Holdings' growth is quite high when compared to the industry average growth of 6.3% in the same period, which is great to see.

接下來,將新開源醫療控股與行業淨利潤增長進行比較,我們發現新開源醫療控股在同一時期的增長率相當高,遠高於行業平均增長率6.3%,這是令人欣慰的。

big
SZSE:300109 Past Earnings Growth October 4th 2024
深圳證券交易所:300109 歷史數據 2024年10月4日 盈利增長

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Boai NKY Medical Holdings is trading on a high P/E or a low P/E, relative to its industry.

估值公司的依據,在很大程度上取決於其盈利增長。投資者需要判斷的下一步是,預期的盈利增長是否已經融入股價,或者未融入其中。這樣做將有助於他們判斷股票的未來是光明還是黑暗。預期盈利增長的一個良好指標是市盈率,它根據企業盈利前景確定市場願意爲股票支付的價格。因此,您可能想要檢查新開源醫療控股股票的市盈率是高還是低,相對於其所屬行業。

Is Boai NKY Medical Holdings Efficiently Re-investing Its Profits?

新開源醫療控股是否有效地重新投資利潤?

Boai NKY Medical Holdings' significant three-year median payout ratio of 57% (where it is retaining only 43% of its income) suggests that the company has been able to achieve a high growth in earnings despite returning most of its income to shareholders.

新開源醫療控股顯著的三年中位數分紅比率爲57%(僅保留收入的43%),表明公司儘管向股東返還大部分收入,仍能實現盈利高增長。

Besides, Boai NKY Medical Holdings has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders.

此外,新開源醫療控股至少連續十年以上支付股息。這表明公司致力於與股東分享利潤。

Conclusion

結論

On the whole, we feel that Boai NKY Medical Holdings' performance has been quite good. Especially the high ROE, Which has contributed to the impressive growth seen in earnings. Despite the company reinvesting only a small portion of its profits, it still has managed to grow its earnings so that is appreciable. Up till now, we've only made a short study of the company's growth data. To gain further insights into Boai NKY Medical Holdings' past profit growth, check out this visualization of past earnings, revenue and cash flows.

總體而言,我們認爲新開源醫療控股的表現相當不錯。特別是高roe,爲收益增長貢獻頗多。儘管公司只是重新投資了一小部分利潤,但仍設法增長收益,這是令人讚賞的。到目前爲止,我們只對公司的增長數據進行了簡短的研究。要了解新開源醫療控股過去利潤增長情況的更多見解,請查看此可視化的過去收益、營業收入和現金流量。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論